{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=azacitidine&page=27", "query": { "intervention": "azacitidine", "page": 27 }, "page_size": 10 }, "pagination": { "page": 27, "page_size": 10, "total_count": 695, "total_pages": 70, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=azacitidine&page=28&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=azacitidine&page=26&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T09:21:50.502Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02269943", "title": "Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nasopharyngeal Neoplasms" ], "interventions": [ { "name": "CC-486", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2015-02-13", "completion_date": "2017-04-20", "has_results": true, "last_update_posted_date": "2018-12-12", "last_synced_at": "2026-10-25T09:21:50.502Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Jefferson City", "state": "Missouri" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02269943" }, { "nct_id": "NCT01333046", "title": "Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkin Lymphoma", "Non-Hodgkin Lymphoma", "Hodgkin Disease" ], "interventions": [ { "name": "Antigen-Escalation Stage", "type": "BIOLOGICAL" }, { "name": "Dose-Escalation Stage", "type": "BIOLOGICAL" }, { "name": "azacytidine and multiTAA T cells Stage", "type": "BIOLOGICAL" }, { "name": "Pediatric multiTAA T cells Stage", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2012-01", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-25T09:21:50.502Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01333046" }, { "nct_id": "NCT05089370", "title": "Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 8, "start_date": "2022-06-20", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-25T09:21:50.502Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05089370" }, { "nct_id": "NCT00118196", "title": "Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "arsenic trioxide", "type": "DRUG" }, { "name": "azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 1, "start_date": "2005-04", "completion_date": "2006-08-11", "has_results": false, "last_update_posted_date": "2018-05-11", "last_synced_at": "2026-10-25T09:21:50.502Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00118196" }, { "nct_id": "NCT01379274", "title": "A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "MDS" ], "interventions": [ { "name": "Lenalidomide and azacitidine combination", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 2, "start_date": "2011-01", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2020-11-19", "last_synced_at": "2026-10-25T09:21:50.502Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01379274" }, { "nct_id": "NCT06694454", "title": "Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)", "Carcinoma, Non-Small Cell Lung", "Non-Small Cell Lung Carcinoma", "Non Small Cell Lung Cancer", "Non Small Cell Lung Carcinoma" ], "interventions": [ { "name": "azacytidine", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "durvalumab", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 60, "start_date": "2026-10-28", "completion_date": "2034-12-31", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-25T09:21:50.502Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06694454" }, { "nct_id": "NCT02190695", "title": "Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndrome", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Arsenic trioxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2013-04-01", "completion_date": "2020-04-16", "has_results": false, "last_update_posted_date": "2021-05-19", "last_synced_at": "2026-10-25T09:21:50.502Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania • Houston, Texas", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02190695" }, { "nct_id": "NCT07645469", "title": "FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Chest Radiography", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2026-10-15", "completion_date": "2030-07-19", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-25T09:21:50.502Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07645469" }, { "nct_id": "NCT00703300", "title": "Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Recurrent Adult Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "decitabine", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2008-06", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2014-11-07", "last_synced_at": "2026-10-25T09:21:50.502Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00703300" }, { "nct_id": "NCT01001143", "title": "Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Bexarotene", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2010-05", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-07-29", "last_synced_at": "2026-10-25T09:21:50.502Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01001143" } ] }